Fuso Pharmaceutical Industries,Ltd. (JP:4538)
:4538
4538 Stock Chart & Stats
¥2315.00
-¥64.00(-2.54%)
At close: 4:00 PM EST
¥2315.00
-¥64.00(-2.54%)
Day’s Range― - ―
52-Week Range¥2,028.00 - ¥2,539.00
Previous CloseN/A
Volume28.90K
Average Volume (3M)17.49K
Market Cap
¥21.26B
Enterprise Value¥43.54B
Total Cash (Recent Filing)¥3.16B
Total Debt (Recent Filing)¥28.23B
Price to Earnings (P/E)5.8
Beta0.65
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.71%
Share Statistics
EPS (TTM)99.84
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.63
Price to Sales (P/S)0.34
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth (9.31% year-on-year) indicates steady demand for hospital-use pharmaceuticals and expanding product volume or market share. Over 2-6 months this supports predictable revenues, aids planning for production capacity, and underpins investment in R&D or portfolio expansion.
Prudent Balance SheetA moderate debt-to-equity ratio and near-50% equity ratio signal financial resilience and borrowing capacity. This balance provides flexibility for capex or acquisitions while limiting leverage risk, supporting long-term stability in a capital-intensive pharmaceutical business.
Stable Profitability MarginsHealthy gross margin and an improving net margin reflect controlled costs and pricing power in hospital-focused products. Sustained margins support reinvestment into manufacturing quality and product development, bolstering competitive positioning over multiple quarters.
Bears Say
Negative Free Cash FlowSignificant negative free cash flow indicates cash generation lags accounting profits, constraining funding for capex, dividends, or deleveraging without raising external capital. Persistent FCF deficits can erode financial flexibility and increase refinancing or dilution risk.
Poor Cash ConversionNegative operating cash flow relative to net income signals weak cash conversion from operations, possibly due to working capital build or receivables. Over time, this stresses liquidity and requires management actions to improve collections, inventory turns, or working capital policies.
Earnings VolatilityA very large negative EPS growth figure points to earnings volatility or prior-period distortions. That volatility undermines forecasting reliability for investors and management, complicates capital allocation, and suggests sensitivity to single-event impacts or pricing and volume swings.
Fuso Pharmaceutical Industries,Ltd. News
4538 FAQ
What was Fuso Pharmaceutical Industries,Ltd.’s price range in the past 12 months?
Fuso Pharmaceutical Industries,Ltd. lowest stock price was ¥2028.00 and its highest was ¥2539.00 in the past 12 months.
What is Fuso Pharmaceutical Industries,Ltd.’s market cap?
Fuso Pharmaceutical Industries,Ltd.’s market cap is ¥21.26B.
When is Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date?
Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date is May 13, 2026 which is in 46 days.
How were Fuso Pharmaceutical Industries,Ltd.’s earnings last quarter?
Fuso Pharmaceutical Industries,Ltd. released its earnings results on Feb 12, 2026. The company reported ¥99.84 earnings per share for the quarter, beating the consensus estimate of N/A by ¥99.84.
Is Fuso Pharmaceutical Industries,Ltd. overvalued?
According to Wall Street analysts Fuso Pharmaceutical Industries,Ltd.’s price is currently Overvalued.
Does Fuso Pharmaceutical Industries,Ltd. pay dividends?
Fuso Pharmaceutical Industries,Ltd. pays a Semiannually dividend of ¥45 which represents an annual dividend yield of 3.71%. See more information on Fuso Pharmaceutical Industries,Ltd. dividends here
What is Fuso Pharmaceutical Industries,Ltd.’s EPS estimate?
Fuso Pharmaceutical Industries,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuso Pharmaceutical Industries,Ltd. have?
Fuso Pharmaceutical Industries,Ltd. has 9,451,169 shares outstanding.
What happened to Fuso Pharmaceutical Industries,Ltd.’s price movement after its last earnings report?
Fuso Pharmaceutical Industries,Ltd. reported an EPS of ¥99.84 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.465%.
Which hedge fund is a major shareholder of Fuso Pharmaceutical Industries,Ltd.?
Currently, no hedge funds are holding shares in JP:4538
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---